Withdrawal studies show that weight regain is common after treatment stops, but they do not predict one person's outcome or establish a universal taper. Plan follow-up around the reason for stopping and the medicine being used.
Semaglutide withdrawal evidence needs its context
In the STEP 1 extension, a subgroup was followed after the trial's semaglutide and lifestyle intervention ended. On average, participants previously receiving semaglutide regained about two-thirds of their earlier weight loss over the following year. This was follow-up of a selected trial subgroup, not a prediction that every person will regain that fraction.
The design also matters: structured lifestyle intervention ended, so the study cannot isolate every influence on regain. STEP 4 used a different design, randomly continuing semaglutide or switching to placebo after an initial treatment period. Together, these studies support a maintenance discussion without answering every question about stopping.
Sources: Diabetes, Obesity and Metabolism: Weight regain after semaglutide withdrawal: STEP 1 extension; JAMA / PubMed: STEP 4: Continued semaglutide versus placebo for weight loss maintenance
Tirzepatide has its own randomised withdrawal trial
SURMOUNT-4 first gave participants tirzepatide for 36 weeks, then randomised those entering the withdrawal phase to continue or switch to placebo. Over the next 52 weeks, the continued-treatment group lost a further 5.5% on average, while the placebo group gained 14.0%, measured from the randomisation point.
Those percentages are changes from week 36, not the proportion of all initial weight loss regained. Participants had already completed an initial treatment period, which limits how directly the results describe someone stopping early because of side effects. Preserve that context when interpreting a headline about regain.
Sources: JAMA: SURMOUNT-4: Continued tirzepatide for maintenance of weight reduction
Do not extend a finding further than the study allows
The injection withdrawal studies do not establish identical outcomes after stopping Wegovy tablets or Foundayo. Different medicines, formulations, treatment durations and participants require their own evidence. Nor does a withdrawal comparison prove that a particular improvised taper or intermittent schedule prevents regain.
If you see a tapering claim, ask whether it comes from a controlled study, a clinical guideline or an anecdote, and whether it concerns your medicine. Do not use pen clicks, leftover extraction or combined tablets to create a schedule. A prescriber should explain any change and its evidence base.
Sources: Diabetes, Obesity and Metabolism: Weight regain after semaglutide withdrawal: STEP 1 extension; JAMA: SURMOUNT-4: Continued tirzepatide for maintenance of weight reduction; Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: patient information leaflet; Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet; Eli Lilly / electronic medicines compendium: Foundayo: patient information leaflet
The reason for stopping determines the priorities
Stopping because of pregnancy, a serious adverse reaction, cost, limited benefit or a planned change in care raises different questions. Some circumstances need prompt cessation and assessment; others allow a planned discussion. Make the reason explicit so a generic maintenance conversation does not obscure an urgent clinical issue.
If the medicine also treats diabetes, arrange a glucose-management plan. Ask which other medicines or monitoring may need review. Do not interpret stopping weight treatment as permission to stop insulin, blood-pressure treatment or another prescription without the relevant clinician's advice.
Sources: NICE: Prescribing, reviewing and stopping tirzepatide; UK Teratology Information Service / BUMPS: GLP-1 receptor agonists in pregnancy; MHRA: GLP-1 medicines: strengthened warnings on acute pancreatitis; Eli Lilly / electronic medicines compendium: Foundayo: patient information leaflet
Write down the follow-up before the last supply ends
Agree who will review weight and relevant health measures, when that review will occur and how to obtain support sooner. Discuss nutrition, activity and practical barriers without promising they will eliminate regain. Keep the last dose and treatment summary available if another clinician takes over.
If weight increases later, use that information to reassess the management plan rather than treating it as a moral failure. Ask what options remain appropriate and affordable. A stopping plan is complete only when it includes the period after the prescription, not simply the date of the last tablet or injection.
Sources: NHS: Overweight and obesity in adults; NICE: Overweight and obesity management: medicines and surgery; NICE: Prescribing, reviewing and stopping tirzepatide
Questions, answered.
Does two-thirds regained mean everyone will regain two-thirds?
No. It is a group result from a particular semaglutide follow-up study, with important design and population limits.
Sources: Diabetes, Obesity and Metabolism: Weight regain after semaglutide withdrawal: STEP 1 extension
Do withdrawal studies prove a home-made taper prevents regain?
No. Discuss any planned dose change with the prescriber rather than creating an untested schedule from the available supply.
Sources: JAMA: SURMOUNT-4: Continued tirzepatide for maintenance of weight reduction; Diabetes, Obesity and Metabolism: Weight regain after semaglutide withdrawal: STEP 1 extension
Sources & further reading
Original sources for this guide. Source checks are not independent clinical review.
- Weight regain after semaglutide withdrawal: STEP 1 extensionDiabetes, Obesity and Metabolism · Accessed 19 November 2026
- STEP 4: Continued semaglutide versus placebo for weight loss maintenanceJAMA / PubMed · Accessed 19 November 2026
- SURMOUNT-4: Continued tirzepatide for maintenance of weight reductionJAMA · Accessed 19 November 2026
- Mounjaro KwikPen: patient information leafletEli Lilly / electronic medicines compendium · Accessed 19 November 2026
- Wegovy tablets: patient information leafletNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- Foundayo: patient information leafletEli Lilly / electronic medicines compendium · Accessed 19 November 2026
- Prescribing, reviewing and stopping tirzepatideNICE · Accessed 19 November 2026
- GLP-1 receptor agonists in pregnancyUK Teratology Information Service / BUMPS · Accessed 19 November 2026
- GLP-1 medicines: strengthened warnings on acute pancreatitisMHRA · Accessed 19 November 2026
- Overweight and obesity in adultsNHS · Accessed 19 November 2026
- Overweight and obesity management: medicines and surgeryNICE · Accessed 19 November 2026
